CVRx, Inc. (CVRX) Tops Q2 EPS by 2c; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
CVRx Reports Second Quarter 2023 Financial and Operating Results
July 25, 2023 4:15 PM EDTMINNEAPOLIS, July 25, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (CVRx), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2023.
Recent Highlights
Total revenue for the second quarter of 2023 was $9.5 million, an increase of 89% over prior year quarterU.S. Heart Failure (HF) revenue for the second quarter of 2023 was... More